News that the FDA has rejected its partner's NDA submission has investors heading for the exits.
News & Analysis: Pain Therapeutics
America's fastest-growing drug problem isn't what you might think. Find out how we're fighting this dangerous problem.
These four stocks could make big moves on the morning of October 30.
The Dow Jones has retreated from triple-digit gains as Pfizer and Johnson & Johnson help keep the index in the green.
An FDA approval, exciting early-stage pancreatic cancer data, the revival of a drug that will not go quietly into the night, and a biotech implosion on disappointing study data are this week's top stories.
Pure speculation has sent the market into losing territory. But the big pharma pack may have just the right medicine for the Dow.
An FDA approval provides a boost to two companies, while two separate clinical updates send shareholders running for the hills.
FDA rulings, comments, and earnings reports take center stage this week.
The "smart money" thinks these potentially undervalued and low risk stocks have more value to cash in. Do you agree?
You love 'em, they hate 'em -- who's got it right?